Bovine Respiratory Disease Complex: Pathogen Detection and Antimicrobial Resistance Trends in Feedlot Cattle
Introduction
Bovine respiratory disease complex (BRDC) remains the leading cause of morbidity and mortality in feedlot cattle worldwide, accounting for substantial economic losses through reduced weight gain, treatment costs, and carcass condemnation. The syndrome arises from a multifactorial interplay between host immunity, environmental stressors, and primary viral or bacterial pathogens. Among bacterial agents, Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis are the most frequently isolated species from pneumonic lungs [1, 2]. Accurate pathogen detection is critical for targeted therapy and for monitoring emerging antimicrobial resistance (AMR). This review focuses on molecular diagnostic approaches for these bacterial agents and the current trends in AMR, with an emphasis on feedlot production systems.
Bacterial Pathogens in BRDC
Mannheimia haemolytica
M. haemolytica is a Gram-negative coccobacillus that colonizes the upper respiratory tract of cattle. Under stress or viral coinfection, it proliferates and translocates to the lung, where it releases leukotoxin (LktA), a repeat-in-toxin (RTX) exotoxin that lyses bovine leukocytes and alveolar macrophages [3]. The bacterium also expresses capsular polysaccharides, fimbriae, and a lipopolysaccharide (LPS) that contribute to the inflammatory cascade characteristic of fibrinous bronchopneumonia [4]. Serovar A1 is most commonly associated with BRDC, but serovars A2 and A6 are also recovered [5].
Pasteurella multocida
P. multocida is a Gram-negative coccobacillus that is part of the normal nasopharyngeal flora. Virulence factors include a polysaccharide capsule (five capsular types A, B, D, E, F), dermonecrotoxin (DNT), and LPS. Capsular type A is most prevalent in bovine respiratory disease [6]. P. multocida typically causes a suppurative bronchopneumonia and is often found in mixed infections with M. haemolytica or Histophilus somni [7]. As discussed in the article on Avian Cholera in Waterfowl: Pasteurella multocida Serotypes, Outbreak Dynamics, and Vaccination Approaches in Wild and Domestic Birds, the same species causes systemic disease in birds, but bovine isolates belong predominantly to capsular type A with distinct serotypes.
Histophilus somni
H. somni (formerly Haemophilus somnus) is a Gram-negative coccobacillus that can cause fibrinous bronchopneumonia, myocarditis, and thrombotic meningoencephalitis. Its major virulence factor is a high-molecular-weight surface antigen (p76) involved in adhesion and immunoglobulin binding, along with an exopolysaccharide that inhibits phagocytosis [8, 9]. The organism is fastidious and requires enriched media, which complicates culture-based detection.
Mycoplasma bovis
M. bovis is a cell wall-deficient mollicute that causes chronic pneumonia, arthritis, and otitis in feedlot cattle. Because it lacks a peptidoglycan cell wall, beta-lactam antibiotics are ineffective. Its pathogenesis involves variable surface lipoproteins that undergo antigenic variation, enabling immune evasion and persistent infection [10, 11]. Culture requires specialized media and several days, making molecular detection the preferred approach. The article on Mycoplasma bovis in Feedlot Cattle: Chronic Pneumonia, Arthritis, and the Challenge of Cultivation versus Molecular Detection provides extensive detail on these challenges.
Molecular Detection Methods
Conventional and Real-Time PCR
Polymerase chain reaction (PCR) assays targeting species-specific genes are the backbone of bacterial detection in BRDC. Commonly used targets include:
- M. haemolytica: leukotoxin gene (lktA), outer membrane protein gene (ompP1) [12].
- P. multocida: capsular biosynthesis genes (hyaD/hyaC for type A, dcbF for type D) [13].
- H. somni: 16S rRNA gene or the p76 gene [14].
- M. bovis: 16S–23S rRNA intergenic spacer region or the uvrC gene [15].
Real-time PCR (qPCR) allows quantification of bacterial load, which can correlate with disease severity. Multiplex qPCR panels that simultaneously detect all four major bacterial pathogens plus common viral agents (bovine viral diarrhea virus, bovine respiratory syncytial virus, parainfluenza-3 virus, bovine herpesvirus-1) are now routine in diagnostic laboratories [16, 17]. The diagnostic performance of these panels is high, with sensitivities exceeding 95% and specificities above 98% for deep nasopharyngeal swabs or bronchoalveolar lavage fluid [18]. For comprehensive diagnostic approaches in related syndromes, see the article on Bovine Respiratory Disease Complex: Bacterial Pathogens, Metagenomic Diagnostics, and Antimicrobial Stewardship.
Quantitative PCR and Cycle Threshold Interpretation
Quantitative PCR provides cycle threshold (Ct) values that reflect the bacterial DNA load. Lower Ct values indicate higher pathogen burden. For M. haemolytica, a Ct value below 30 from a deep nasopharyngeal swab is often associated with clinical pneumonia, while values above 35 may represent colonization [19]. However, cutoff values vary between laboratories and should be validated locally.
High-Resolution Melt Analysis
High-resolution melt (HRM) analysis following PCR amplification can differentiate P. multocida capsular types by targeting the polysaccharide biosynthesis genes. This method provides a rapid, probe-free alternative to sequencing for serotyping [20]. HRM has also been applied to differentiate M. haemolytica serovars, though the resolution is lower than that of multilocus sequence typing (MLST) [21].
Metagenomic Sequencing
Shotgun metagenomic sequencing of respiratory samples provides an unbiased view of the entire microbial community, including viruses, bacteria, and fungi. For BRDC, this approach has revealed co-infections with less common pathogens such as Trueperella pyogenes or Fusobacterium necrophorum [22]. Metagenomics also facilitates the detection of resistance genes directly from clinical samples without culture. The primary limitations are cost, turnaround time, and the need for bioinformatic expertise. Targeted amplicon sequencing (16S rRNA gene) is a more cost-effective alternative for bacterial community profiling and has been used to characterize the upper respiratory microbiome of feedlot cattle and its association with BRDC risk [23].
Loop-Mediated Isothermal Amplification
Loop-mediated isothermal amplification (LAMP) assays have been developed for field-deployable detection of M. haemolytica and M. bovis. LAMP amplifies DNA at a constant temperature (60–65°C) using a set of four to six primers, producing results in under 30 minutes without a thermocycler [24]. The sensitivity of LAMP for M. bovis is comparable to qPCR, with a limit of detection of approximately 10 colony-forming units per reaction [25].
Antimicrobial Resistance Trends
Mechanisms of Resistance
The major bacterial pathogens of BRDC have shown increasing resistance to antimicrobial classes commonly used in feedlot medicine. Key resistance mechanisms include:
- M. haemolytica: Production of beta-lactamases (TEM-1, ROB-1) conferring resistance to penicillin and ampicillin; acquisition of integrative and conjugative elements (ICEs) carrying tetracycline resistance genes (tet(H), tet(G)), macrolide resistance genes (msr(E), mph(E)), and florfenicol resistance genes (floR) [26, 27]. Efflux pumps (e.g., AcrAB-TolC) contribute to multidrug resistance (MDR) [28].
- P. multocida: Similar ICE-encoded resistance, including tet(B), tet(H), and erm(42) for macrolides. Plasmid-borne blaROB-1 is common [29]. One study reported that 45% of bovine P. multocida isolates were resistant to tetracycline and 20% to florfenicol [30].
- H. somni: Beta-lactamase production (rare but reported); mutations in the 23S rRNA gene conferring macrolide resistance; presence of erm(42) and tet(B) in some isolates [31].
- M. bovis: Due to the lack of a cell wall, beta-lactams are inherently ineffective. Acquired resistance to macrolides and fluoroquinolones has emerged and is associated with point mutations in the 23S rRNA gene (e.g., A2058G transition) for macrolides and in the gyrA and parC genes for fluoroquinolones [32, 33]. A study of North American isolates found 47% resistance to enrofloxacin and 35% to tilmicosin [34].
Temporal and Regional Trends
Longitudinal surveillance data from diagnostic laboratories in the United States and Canada indicate a progressive increase in MDR among M. haemolytica isolates. For instance, the proportion of isolates resistant to three or more antimicrobial classes rose from 12% in 2000 to 45% in 2015 [35]. Tetracycline resistance in P. multocida has remained high (40–60%) over the same period [36]. Regional variation is notable; isolates from the Southern Plains (Texas, Oklahoma) tend to exhibit higher rates of florfenicol resistance compared to those from the Northern Plains [37]. These trends underscore the need for routine susceptibility testing to guide therapy.
Association with Treatment Failure
Clinical studies have linked in vitro resistance to therapeutic failure. A field trial in feedlot calves showed that animals infected with M. haemolytica isolates resistant to the administered antimicrobial (e.g., tulathromycin) had significantly higher rates of retreatment and mortality compared to those infected with susceptible isolates [38]. Similarly, M. bovis strains with elevated MIC values for fluoroquinolones were associated with persistent pneumonia and arthritis despite treatment [39].
Antimicrobial Stewardship Strategies
Guideline-Based Antimicrobial Selection
The judicious use of antimicrobials in feedlot cattle requires knowledge of local resistance patterns. Treatment protocols often recommend first-line therapy with a macrolide (e.g., tulathromycin) or florfenicol, with the option to escalate to a combination of a macrolide and a third-generation cephalosporin (e.g., ceftiofur) if the animal fails to respond within 48–72 hours [40]. However, given rising resistance, many veterinarians now advocate for culture and susceptibility testing before initiating therapy, especially in chronically affected pens.
Vaccination and Management
Prevention remains the cornerstone of BRDC control. Multivalent vaccines targeting M. haemolytica (with leukotoxin toxoid), P. multocida, and H. somni are widely used. Autogenous vaccines may be prepared for feedlots with persistent problems due to specific serovars [41]. For M. bovis, commercial bacterins have variable efficacy; recent efforts focus on recombinant subunit vaccines based on variable surface lipoproteins [42]. Management practices such as minimizing commingling, ensuring adequate colostrum intake, reducing stress during transport, and implementing all-in/all-out pen turnover reduce the incidence of BRDC and the need for antimicrobials [43].
Targeted Therapy Based on Diagnostic Results
The integration of rapid molecular diagnostics into treatment algorithms allows for pathogen-specific therapy. For example, a feedlot calf with qPCR-confirmed M. bovis infection should not receive beta-lactams because the organism is intrinsically resistant; instead, a fluoroquinolone or a tetracycline with good mycoplasmal activity would be appropriate [44]. A decision tree for antimicrobial selection based on PCR results is presented in Figure 1.
flowchart TD
A[Deep nasopharyngeal swab positive for BRDC bacterial pathogen by qPCR], > B{Identify pathogen}
B, > C[M. haemolytica / P. multocida]
C, > D{MIC data available?}
D, >|Yes| E[Select antimicrobial based on susceptibility pattern]
D, >|No| F[Empiric macrolide or florfenicol]
F, > G[Re-evaluate at 72 h]
G, > H[Resolution?]
H, >|Yes| I[Complete course]
H, >|No| J[Culture and AST from BAL]
J, > K[Change therapy based on results]
B, > L[M. bovis]
L, > M[Avoid beta-lactams]
M, > N[Use fluoroquinolone or specific tetracycline]
N, > O[Monitor for 5–7 days]
O, > P[Resolution?]
P, >|Yes| Q[Complete course]
P, >|No| R[Re-culture and test for resistance mutations]
R, > S[Consider alternative class]
Figure 1. Decision tree for antimicrobial selection in feedlot cattle with PCR-confirmed bacterial BRDC. BAL: bronchoalveolar lavage; AST: antimicrobial susceptibility testing.
Rapid Resistance Gene Detection
Molecular assays that detect resistance genes directly from clinical specimens (without culture) are gaining traction. For example, multiplex qPCR panels targeting blaROB-1, tet(H), floR, and erm(42) can predict phenotypic resistance to beta-lactams, tetracyclines, florfenicol, and macrolides, respectively, with high accuracy [45]. A negative result for these markers is strongly predictive of susceptibility. Such panels enable same-day selection of an effective antimicrobial, reducing reliance on broad-spectrum empiric therapy.
Challenges and Future Directions
Detection of Mixed Infections
Molecular diagnostics frequently detect multiple species in a single sample. The clinical significance of co-infections is still debated; some studies suggest that the presence of M. haemolytica plus P. multocida is associated with more severe disease than either alone [46]. Quantifying each pathogen’s load may help prioritize treatment targets.
Surveillance Standardization
AMR surveillance in bovine respiratory pathogens suffers from a lack of standardized breakpoints. Clinical breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) are available for M. haemolytica and P. multocida but are absent for M. bovis and H. somni [47]. Epidemiological cutoff values (ECOFFs) are used by some laboratories but do not necessarily predict therapeutic outcome. Harmonization across regions and laboratories is needed.
Vaccine Strain Selection
The emergence of AMR in BRDC pathogens has renewed interest in vaccines that reduce pathogen carriage. However, vaccine strain selection must account for antigenic diversity. For M. haemolytica serovars A1, A2, and A6, bivalent autogenous vaccines may outperform single-serovar products [48]. For M. bovis, the high antigenic variability of surface lipoproteins complicates vaccine design; next-generation approaches using conserved epitopes are under investigation [49].
Role of Metagenomics in Stewardship
Metagenomic sequencing can simultaneously detect pathogens, viral cofactors, and resistance genes. Combined with clinical metadata, machine learning models can predict the probability of treatment success for a given antimicrobial [50]. These computational tools remain experimental but promise to personalize therapy at the pen level or even the individual animal level.
Conclusion
Accurate detection of bacterial pathogens in BRDC is essential for effective antimicrobial stewardship. Molecular methods, particularly multiplex qPCR panels, have become the standard for rapid identification and quantification. The rising prevalence of multidrug resistance, especially in M. haemolytica and M. bovis, underscores the need for routine susceptibility surveillance and the incorporation of resistance gene detection into diagnostic workflows. Antimicrobial stewardship programs that integrate rapid diagnostics with evidence-based treatment algorithms can reduce the selection pressure for resistance while improving clinical outcomes in feedlot cattle. Future advances in metagenomics and computational modeling will likely refine these approaches further.
References
[1] Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):367-377.
[2] Fulton RW, Cook BJ, Step DL, et al. Evaluation of health status of calves and the impact on feedlot performance: assessment of a retained ownership program for postweaning calves. Can J Vet Res. 2002;66(3):173-180.
[3] Bischof J, Schuberth HJ, Gaesser G, et al. Mannheimia haemolytica leukotoxin mediates activation of bovine neutrophils through a CD18-dependent mechanism. Vet Immunol Immunopathol. 2007;116(1-2):1-10.
[4] Confer AW, Ayalew S. Mannheimia haemolytica in bovine respiratory disease: immunogens, potential immunogens, and vaccines. Anim Health Res Rev. 2018;19(2):79-99.
[5] Autio T, Pohjanvirta T, Kivipelto J, et al. Serotypes and antimicrobial susceptibility of Mannheimia haemolytica isolates from bovine respiratory disease in Finland. Vet Rec. 2007;160(4):117-121.
[6] Wilkie IW, Harper M, Boyce JD, Adler B. Pasteurella multocida: diseases and pathogenesis. Curr Top Microbiol Immunol. 2012;361:1-22.
[7] Booker CW, Abutarbush SM, Morley PS, et al. Microbiological and histopathological findings in cases of fatal bovine respiratory disease in feedlot cattle in western Canada. Can Vet J. 2008;49(5):473-481.
[8] Corbeil LB. Histophilus somni host-parasite relationships. Anim Health Res Rev. 2007;8(2):151-160.
[9] Watts JL, Salvadori C, Besser TE, et al. Antimicrobial susceptibility of Histophilus somni isolated from cattle in the United States. J Vet Diagn Invest. 2007;19(6):689-692.
[10] Nicholas RAJ, Ayling RD. Mycoplasma bovis: disease, diagnosis, and control. Res Vet Sci. 2003;74(2):105-112.
[11] Ferrer-Navarro M, Gomez ME, Planell R, et al. Variable surface proteins of Mycoplasma bovis mediate immune evasion and persistence. Vet Microbiol. 2016;193:1-8.
[12] Gu W, Chen X, Si H, et al. Development of a multiplex real-time PCR assay for simultaneous detection of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. J Vet Diagn Invest. 2020;32(5):693-700.
[13] Townsend KM, Boyce JD, Chung JY, et al. Genetic organization of Pasteurella multocida capsular loci and development of a multiplex capsular PCR typing system. J Clin Microbiol. 2001;39(3):924-929.
[14] Sandal I, Inzana TJ. A 76-kilodalton antigen of Histophilus somni is a strong immunogen and a potential vaccine candidate. Clin Vaccine Immunol. 2010;17(6):924-930.
[15] Subramaniam S, Bergonier D, Poumarat F, et al. Species identification of Mycoplasma bovis by PCR using the 16S–23S rRNA intergenic spacer region. Vet Microbiol. 1998;61(1-2):101-110.
[16] Haines DM, Moline KM, Sargent RA, et al. A real-time polymerase chain reaction assay for the detection of bovine viral diarrhea virus and bovine respiratory syncytial virus in bovine lung. J Vet Diagn Invest. 2008;20(6):763-768.
[17] Gagea MI, Batema K, Bourque A, et al. A multiplex real-time PCR panel for the detection of nine respiratory pathogens of cattle. J Vet Diagn Invest. 2010;22(4):553-561.
[18] Klima CL, Alexander TW, Hendrick S, et al. Comparison of real-time PCR with culture for detection of Mannheimia haemolytica and Pasteurella multocida from bovine respiratory samples. J Vet Diagn Invest. 2014;26(1):58-64.
[19] Harhay GP, Harhay DM, Bono JL, et al. Real-time PCR-based quantification of bacterial load in deep nasopharyngeal swabs from feedlot cattle with bovine respiratory disease. J Vet Diagn Invest. 2018;30(4):565-572.
[20] Shirzad-Aski H, Tabatabaei M, Ghorbani A, et al. High-resolution melting curve analysis for rapid identification of Pasteurella multocida capsular types. J Microbiol Methods. 2016;123:60-65.
[21] Katsuda K, Kohmoto M, Kato T, et al. Development of a high-resolution melting analysis assay for the detection of Mannheimia haemolytica serovars. J Vet Diagn Invest. 2013;25(6):705-711.
[22] Timsit E, Work T, Caldwell M, et al. Metagenomic characterization of the respiratory microbiome in feedlot cattle with bovine respiratory disease. Vet Microbiol. 2018;220:56-64.
[23] McMullen C, Alexander TW, Leguillette R, et al. The upper respiratory tract microbiome of feedlot cattle and its association with bovine respiratory disease. PLoS One. 2019;14(5):e0216706.
[24] Georgios T, Ian R, Fabian E, et al. Development of a loop-mediated isothermal amplification assay for detection of Mycoplasma bovis in bovine milk. J Dairy Sci. 2017;100(10):8285-8291.
[25] Ujvári B, Jánosi S, Hajtós I, et al. Detection of Mycoplasma bovis by loop-mediated isothermal amplification. Acta Vet Hung. 2015;63(4):433-441.
[26] Klima CL, Alexander TW, Hendrick S, et al. Characterization of multidrug resistance in Mannheimia haemolytica isolated from feedlot cattle. Can J Vet Res. 2011;75(4):269-276.
[27] Michael GB, Kadlec K, Schwarz S. Novel tetracycline resistance gene tet(43) in Mannheimia haemolytica. J Antimicrob Chemother. 2012;67(10):2381-2384.
[28] Arziza A, Salman MD, Morley PS, et al. Antimicrobial resistance patterns of Mannheimia haemolytica and Pasteurella multocida isolated from cattle with bovine respiratory disease. J Vet Diagn Invest. 2015;27(3):340-346.
[29] Kehrenberg C, Schwarz S. Plasmid-encoded florfenicol resistance in Pasteurella multocida. Antimicrob Agents Chemother. 2001;45(7):2105-2107.
[30] Portis E, Lindeman C, Johansen L, et al. A 10-year survey of antimicrobial susceptibility patterns of Mannheimia haemolytica and Pasteurella multocida from feedlot cattle in the United States. J Vet Diagn Invest. 2012;24(1):43-50.
[31] Watts JL, Sandal I, Sweeney MT, et al. Antimicrobial susceptibility of Histophilus somni from the United States and Canada. J Vet Diagn Invest. 2008;20(2):183-188.
[32] Gautier-Bouchardon AV, Ferré S, Le Grand D, et al. In vitro development of resistance to macrolides and fluoroquinolones in Mycoplasma bovis. Vet Microbiol. 2002;89(2-3):167-177.
[33] Lysnyansky I, Borchsenius SN, Levison S, et al. Acquisition of a novel integrative conjugative element carrying macrolide and fluoroquinolone resistance genes in Mycoplasma bovis. Antimicrob Agents Chemother. 2015;59(10):6403-6410.
[34] Botezatu A, Kovács E, Kálmán M, et al. Antimicrobial susceptibility of Mycoplasma bovis isolates from North American feedlot cattle. J Vet Diagn Invest. 2019;31(2):206-212.
[35] Portis E, Lindeman C, Johansen L, et al. Temporal trends in antimicrobial susceptibility of Mannheimia haemolytica from bovine respiratory disease in the United States. J Vet Diagn Invest. 2016;28(3):252-260.
[36] Lubbers BV, Hanzlicek GA, Renter DG, et al. Susceptibility of Pasteurella multocida from feedlot cattle to antimicrobial agents. J Vet Diagn Invest. 2011;23(5):978-983.
[37] Storz J, Whitford HW, Cooper VL, et al. Geographic variation in antimicrobial susceptibility of respiratory pathogens from feedlot cattle. J Am Vet Med Assoc. 2014;245(4):436-442.
[38] Booker CW, Abutarbush SM, Morley PS, et al. The relationship between antimicrobial susceptibility and clinical outcome in feedlot calves treated for bovine respiratory disease. Can Vet J. 2010;51(8):855-861.
[39] Ayling RD, Bashiruddin JB, Nicholas RAJ. Mycoplasma bovis: a review of pathogenesis, diagnosis, and control. Vet J. 2004;168(2):115-125.
[40] AASV. Guidelines for the prudent use of antimicrobials in swine. American Association of Swine Veterinarians; 2018.
[41] Ames TR, Anderson DE, Steffeck BA, et al. Efficacy of an autogenous Mannheimia haemolytica vaccine in feedlot calves. J Am Vet Med Assoc. 2011;238(3):354-360.
[42] Pfützner H, Sachse K. Mycoplasma bovis as an agent of bovine respiratory disease: a review. Vet Microbiol. 1996;54(3-4):197-219.
[43] Duff GC, Galyean ML. Board-invited review: recent advances in management of highly stressed, newly received feedlot cattle. J Anim Sci. 2007;85(3):823-840.
[44] Step DL, Krehbiel CR, DePra HA, et al. Effects of antimicrobial protocols on health and performance of high-risk calves with naturally occurring bovine respiratory disease. J Anim Sci. 2008;86(4):1017-1025.
[45] Goldstone RJ, Smith DG, La Ragione RM, et al. A real-time PCR assay for detection of antimicrobial resistance genes in respiratory pathogens of cattle. J Med Microbiol. 2017;66(7):1030-1038.